• Waleed A Al-Dahi, Saeed H Khalaf, Dalal A AlRomaihi, Naji M Alamuddin, Hessa M Al Kandari, Doaa K Abdalla, Hanan Y Alfadehla, Amin A Jayyousi, Mashhood A Siddique, Usama A AlAlami, Guruprasad C Subbarao, Shashikanth J Chetty, and Jehan A Abdulla.
• From the Department of Internal Medicine (Al-Dahi), Mubarak Hospital, Al Jairiyah; from the Department of Pediatric Endocrinology (Al Kandari), Farwaniya Hospital; from the Department of Endocrinology (Al Kandari, Abdalla), Dasman Diabetes Institute, Dasma; from the Department of Primary Care (Abdalla, Alfadehla) Yarmouk Primary Health Care Centre, Al Yarmūk; from the Department of Medical Affairs (AlAlami, Subbarao, Chetty), Novo Nordisk Gulf Cluster, Salmiya, Kuwait; from the Department of Endocrinology (Khalaf), Salmaniya Medical Complex, Manama; from the Department of Endocrinology (AlRomaihi), Awali Hospital, Awali; Department of Internal Medicine (Alamuddin), King Hamad University Hospital, Adliya; from the Department of Endocrinology (Abdulla), Bahrain Defence Force Hospital, West Riffa, Bahrain; and from the Department of Endocrinology (Jayyousi, Siddique), Hamad Medical Corporation, Doha, Qatar.
• Saudi Med J. 2025 Feb 1; 46 (2): 163170163-170.

ObjectivesTo provide insights into the real-world usage of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) among individuals with type 2 diabetes (T2D) from Bahrain, Kuwait, and Qatar who either had established atherosclerotic cardiovascular disease (eASCVD) or were at high risk of developing ASCVD.MethodsThis study of 1062 adults diagnosed with T2D from Bahrain, Kuwait, and Qatar is a sub-analysis within the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients with Type 2 Diabetes across Countries in the Middle East and Africa (PACT-MEA) study, a noninterventional, cross-sectional study. Participants were recruited from 13 primary or secondary care facilities between March and August 2022. Medical records of participants were reviewed to extract relevant data, including demographic characteristics, eASCVD status, ASCVD risk and glucose-lowering treatment. Appropriate descriptive and inferential statistical tests were performed.ResultsAmong T2D participants with eASCVD, a significantly higher proportion (41.3%) received SGLT2i compared to GLP-1RA (10.5%, p<0.001). There were notable variations in GLP-1RA/SGLT2i utilization across countries (p<0.001): being lowest in Bahrain (2.3%/18.0%), 26.9%/58.2% in Kuwait and 10.5%/67.1% in Qatar. The use of both medications was significantly higher in individuals with body mass index (BMI) ≥30 kg/m2 (p<0.05).ConclusionDespite these cardioprotective agents being recommended by guidelines, the study findings suggest a suboptimal use of GLP-1RA and SGLT2i in a real-world setting.Copyright: © Saudi Medical Journal.

30 keywords...

hide…